You are here

News

2018     i     2017     i     2016     i     2015     i     2014     i     2013     i     2012
 


- 2018 -



May 28, 2018


The New York Times
‘Paying Twice’: A Push for Affordable Prices for Taxpayer-Funded Drugs

On Aug. 30, the Food and Drug Administration approved a radical new cancer treatment that harnesses a patient’s immune system to attack tumor cells. The drug, known as Kymriah, grew out of research conducted and supported by the National Institutes of Health. Seven weeks later the F.D.A. approved a second cancer therapy that uses similar technology. This treatment, Yescarta, “got its start right here at N.I.H.,” said Dr. Francis S. Collins, the director of the health institutes. It was developed by Kite Pharma using technology licensed from the N.I.H. Kymriah costs $475,000 for a one-time treatment, and Yescarta goes for $373,000. As President Trump vows to lower prescription drug prices, consumer advocates and health policy experts are increasingly saying that the government should insist on reasonable prices for drugs developed with taxpayer funds. [...]

 



May 7, 2018


STAT
The Miracle of Medicines

We don’t know what induced an ancestral human in pain to eat the seed head of the opium poppy. We do know, from the Ebers papyrus, that by 1500 B.C. the Egyptians were using complex mixtures of plants as medicine, and that they realized there was a fine line between doses that improved health and doses that caused toxicity. Opium might bring relief from pain, but it also caused sleepiness, addiction, and even death. Until relatively recently, all drug discovery began with folklore and folk medicine, like the elderly woman in the 1770s telling William Withering that her recipe for dropsy (heart failure) included the purple foxglove plant, which contained digitalis. [...]

 



February 27, 2018


NIH Director's Blog
Basic Research: Building a Firm Foundation for Biomedicine

A major part of NIH’s mission is to support basic research that generates fundamental knowledge about the nature and behavior of living systems. Such knowledge serves as the foundation for the biomedical advances needed to protect and improve our health—and the health of generations to come. Of course, it’s often hard to predict how this kind of basic research might benefit human populations, and the lag time between discovery and medical application (if that happens at all) can be quite long. Some might argue, therefore, that basic research is not a good use of funds, and all of NIH’s support should go to specific disease targets. [...]

 



February 23, 2018


CBC News
How many new drugs rely on government-funded science? All of them

There's public science in every single new drug. That was the surprising answer to a U.S. senator's question about how government-funded research is benefitting citizens. But it took a year to come up with the numbers. It all started last June when Bentley University professor Fred Ledley and his colleagues in Massachusetts were watching a senate budget hearing that was considering cutting the budget of the National Institutes of Health, the major medical science funding agency in the U.S. [...]

 



February 13, 2018


The Center for Biosimilars
Is the White House Budget at Odds With NIH's Contributions to New Drugs?

Yesterday, President Trump released his budget proposal for the 2019 fiscal year. Under the proposed plan, the National Institutes of Health (NIH) budget for 2019 would remain about equal to its 2017 budget: $34.8 billion. However, this figure would be roughly $2 billion less than the 2018 budget that was just approved by Congress on February 8.... On the same day that Trump put forward his budget proposal, the Proceedings of the National Academy of Sciences of the United States of America (PNAS) released a paper summarizing the NIH’s contribution of funding to new drugs approved from 2010 to 2016. [...]

 



February 12, 2018


STAT
NIH funding contributed to 210 approved drugs in recent years, study says

A new study makes a strong case for the importance of government support for basic research: Federally funded studies contributed to the science that underlies every one of the 210 new drugs approved between 2010 and 2016. Researchers at Bentley University scoured millions of research papers for mentions of those 210 new molecular entities, or NMEs, as well as studies on their molecular targets. Then, they looked to see which of those studies had received any funding from the National Institutes of Health. [...]

 



February 2018


PNAS
Contribution of NIH funding to new drug approvals 2010–2016

View a continuously updated news feed of Contribution of NIH funding to new drug approvals 2010–2016

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America

 



February 12, 2018


Bentley University: PreparedU
Bentley University Study Shows NIH Spent More Than $100 Billion on Basic Science for New Medicines

Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University. The new report from the Center for Integration of Science and Industry at Bentley University, published in the Proceedings of the National Academy of Sciences, shows that the United States government invested more than $100 billion in the basic research that led to new medicines approved by the Food and Drug Administration (FDA) between 2010 and 2016. [...]

Additional coverage on Medical Xpress & Science Newsline

 



January 25, 2018


Bentley University: PreparedU
Thirty Years of Innovation Pays Off as Gene-based Drugs Come to Market

The recent approval of SpinrazaTM (nusinersen), jointly developed by Ionis Pharmaceuticals and Biogen, marks the arrival of a new class of biological products - oligonucleotide therapeutics, or gene-based drugs. A recently published study from Bentley's Center for Integration of Science and Industry shows that the thirty year path from the initiation of research on oligonucleotides as therapeutics to the emergence of effective products followed predictable patterns of innovation, in which novel products are successfully developed only after the underlying basic research reaches a requisite level of maturity. [...]

 


- 2017 -



July 12, 2017


Waltham Public Library
Frankenfood or Promethean Promise? Science and Food Production

The foods we eat, whether “organic, “natural, or “locally sourced,” are no longer of nature. The strains of vegetables that we grow and subspecies of animals we use for milk and meat would be unrecognizable to our ancestors and unsuccessful in the wild. Even before the modern era of molecular genetic engineering, all of our foods have been subject to millennia of cross breeding and human selection. Have we created Frankenfoods, or a Promethean promise of sustainable future? Bentley University Professor Fred D. Ledley talks genetically modified foods at the Waltham Public Library. [...]

 



May 8, 2017


Bentley University: PreparedU
21st Century Cures Emerge As 20th Century Science Matures

Most of the new drugs approved by the FDA since 2010 arose from basic scientific research that was initiated in the 1970s or 1980s, a new study from Bentley University has found. The analysis shows that development of new targeted and biological therapeutics rest on the maturation of basic science over decades. The research, published today in the journal PLOS ONE, appears as scientists are increasingly concerned about federal support for basic biomedical research.  [...]

 



March 28, 2017


BioWorld
Translation takes time: Study shows how to measure it properly

The lag between the initiation of new research and the approval of targeted or biologic drugs for treating cancer can exceed 40 years, according to a newly published analysis that examines the relationship between the maturation of technologies and their potential to generate successful products. To casualties of the early era of antibody development, the conclusion might appear obvious. [...]

 



March 27, 2017


Boston Business Journal
NIH cuts might cause 40 years of pain, Bentley study says

Massachusetts researchers say the effects of slashing funding for the National Institutes of Health could have negative impacts on scientific discovery for decades. Researchers at Bentley University reported in a study published this week in the science journal PLOS One that it takes over a decade and upward of 40 years for the discoveries coming from basic research to fuel commercial drugs and technologies. [...]

 



March 27, 2017


Bentley University: PreparedU
New Study Demonstrates the Importance of Long-Term Funding for Cancer Research

New drugs to treat cancer that are now emerging are the end products of research begun in the 1970s and ‘80s, a new study by Bentley University has found, demonstrating the importance of long-term research in bringing new therapies to market. The research, published today in the journal PLOS One, appears as Congress considers deep cuts to the National Institutes of Health, whose budget funds research into cancer and other diseases. [...]

 


- 2016 -



December 19, 2016


Bentley University: PreparedU
Center for Integration of Science and Industry Expands Data Analytics Capabilities with New Appointments

Expanding its capabilities in the application of machine learning, big data and analytics to accelerate the translation of scientific discoveries into new medicines and treatments for diseases, the Center for Integration of Science and Industry at Bentley University has appointed Ekaterina Galkina Cleary, PhD, as a postdoctoral fellow and R. Mark Adams, PhD, as a visiting faculty in the Department of Natural and Applied Sciences. [...]

 



December 8, 2016


Bentley University: PreparedU
Could Edible Algae Hold the Key to Slowing Climate Change? Bentley Fellow Forecasts Yes.

Scientists affiliated with the Marine Algal Industrialization Consortium have published a research article demonstrating the potential of using microalgae (algae) to significantly mitigate greenhouse gas emissions if used as a source of food. Leading the study was Michael J. Walsh, a research fellow in Bentley University’s Center for Integration of Science and Industry [...]

 


November 29, 2016


Bloomberg L.P.
Fred Ledley on Bloomberg Radio: Finding the Proper Dose of Skills for Success in the Health Care Industry

Listen in as Dr. Fred Ledley, director of Bentley University's Center for Integration of Science and Industry (CISI), joins Bentley President Gloria Larson and Bloomberg Radio's Carol Massar and Cory Johnson to discuss the similar frameworks of business and healthcare. [Audio clip of Dr. Ledley]

 



October 18, 2016


Bentley University: PreparedU
Why Business Students Should Care About the Story of the Drug Humira

Developing new medicines is a hard business. While we live in an era of amazing discoveries in biomedical science, information technology, and medicine, there have not been comparable advances in the development of new drugs or the outcomes of major diseases. Why? Research at Bentley University suggests that it is often because innovative technologies are not in sync with business strategies and public policy. [...]

 



July 19, 2016


Bentley University: PreparedU
At the Forefront of Sustainable Food, Bentley Research Fellow Brings Algae to the Table

Think the bright green substance that might be overtaking your neglected fish tank is useless? Think again. Though it would be too difficult to harness the power of that naturally occurring fish tank algae, a Bentley scientist is working to create economic value from algae that can be intentionally and sustainably produced in mass quantities. [...]

 



March 1, 2016


Macquarie University
Vice-Chancellor welcomes Professor Ledley to campus

The Vice-Chancellor welcomed Professor Fred Ledley to campus last week, and provided an introduction to a guest lecture given to the University. Professor Ledley is the Director of the Centre for Integration of Science and Industry at Bentley University, and an expert in the commercialization of medical technology and developments. [...]

 



February 19, 2016


Bentley University: PreparedU
Center for Integration of Science and Industry Receives $2.3M in Funding

Bentley’s Center for Integration of Science and Industry, founded in 2013 with a $1.3M grant from the National Biomedical Research Foundation (NBRF), was awarded renewed funding from the NBRF: $2.3M over the next five years [...]

 


- 2015 -


December 1, 2015
 

Bloomberg L.P.
Fred Ledley on Bloomberg Radio: FDA Approves Genetically Modified Salmon (Audio)

Listen in as Dr. Fred Ledley, director of Bentley University's Center for Integration of Science and Industry (CISI), and Aaron Kennon, Co-Founder and Chief Executive Officer of Clear Harbor Asset Management and board member of the Atlantic Salmon Federation, discuss the FDA's approval of genetically modified salmon.

 


December 1, 2015
 


ETF News
Are Self-Driving Cars Headed For Your Portfolio?

Fred Ledley commented on the future of self-driving cars, emphasizing that “Experience teaches that computers are actually better at decision-making capability than humans. Humans tend to overestimate the value of 'experience' and 'feel,' and rarely compete successfully against computers and algorithms dedicated to particular purposes.”


November 20, 2015


The Boston Globe
FDA Approves Genetically Modified Salmon

The genetically engineered fish, named the AquAdvantage salmon, is produced by AquaBounty, a Maynard biotechnology company based in Massachusettes. With the FDA's OK, AquaBounty can now offer its modified salmon to American consumers.


October 27, 2015


Bentley University: PreparedU
Why a Business University and Its Students Should Be Invested in Healthcare Reform

The challenges facing our national healthcare system are undoubtedly among the most pressing concerns of our nation. With an aging population, healthcare costs escalating, and patient need increasing, we must look more than ever to innovative solutions. So what can a university do to prepare tomorrow’s future business leaders to help reform the healthcare system? [...]


October 9, 2015


Boston Business Journal
ViewPoint: Drug pricing is about worth, not the cost

High drug prices are a target for politicians. In Massachusetts, proposed legislation would limit drug prices and require drug companies to divulge research, marketing and production costs [...]


August 18, 2015


Bentley University: PreparedU
Bentley University Study Suggests Alzheimer’s Research is Ready to Provide Cures

It has been more than a decade since a new drug was approved for the nearly 5 million Americans suffering from Alzheimer’s disease. Research from the Center for Integration of Science and Industry at Bentley University offers a hopeful view of the prospects for new Alzheimer’s drugs [...]


July 2, 2015

Bloomberg L.P.
Fred Ledley on Bloomberg Radio: 2015 - Activists Battling Biotech (Audio)

Dr. Fred Ledley, Director of Bentley University's Center for Integration of Science and Industry, discusses activists battling biotech companies.


July 1, 2015

Bloomberg L.P.
Fred Ledley on Bloomberg Radio: Do stock buybacks compete with corporate R&D? (Audio)

Listen in on Dr. Fred Ledley, director of Bentley University's Center for Integration of Science and Industry (CISI), offer insight on how biotechnology companies are increasingly at odds with activist investors.


July 1, 2015

Science Direct
Algal Biofuel Production for Fuel and Feed in a 100-ha Facility

A comprehensive techno-economic analysis and life cycle assessment based on actual production by the Cornell Marine Algal Biofuels Consortium with biomass productivity > 23 g/m2-day.


June 18, 2015

International Innovation
Nurturing the fruits of scientific discovery

Fred Ledley, opinion leader in the integration of science, business and education, discusses why business models matter in innovation and how societal impact can be enhanced by more efficiently aligning science and industry.


February 16, 2015

American Association for the Advancement of Science
AAAS 2015 Annual Meeting Session - The Business of Innovation: Great Science Is Only the First Step

Fred Ledley discusses the business of innovation with Karen Bernstein, Co-Founder and Chairman of BioCentury, and Gail Naughton, CEO and Chairman of the Board of Histogen Inc.


February 11, 2015

Bentley University: PreparedU
Post-Doctoral Fellow Appointed to Research Treatment for Neurodegenerative Diseases

Expanding its research on how to accelerate the translation of scientific discoveries into new medicines, the Center for Integration of Science and Industry at Bentley University has appointed Jennifer Beierlein as a post-doctoral fellow.  Beierlein will focus on strategies and policies that may lead to new treatments for neurodegenerative diseases including Alzheimer’s, Dementia and Parkinson’s disease [...]

 


- 2014 -
(Back to top)


June 11, 2014

Bentley University
Fred Ledley: Testifies to Congressional Committee on Energy and Commerce

Dr. Fred Ledley's testimony focuses on business incentives that encourage the development of the highly innovative medicines that are being enabled by the rapid advance of science, including some of the work being done at the Center for Integration of Science and Industry at Bentley University. 


June 11, 2014

Bloomberg L.P.
Fred Ledley on Bloomberg's Taking Stock Radio Program: Comments on 21st Century Cures Act (Audio)

Listen in on Fred Ledley, director of Bentley University's Center for Integration of Science and Industry (CISI), and Sam Fazeli, director of research and senior pharmaceutical analyst for Bloomberg Industries, discuss advances in the health care industry geared towards getting drugs to patients more quickly.


June 11, 2014

Bentley University: PreparedU
Bentley Professor Advocates Incentives to Leverage 21st-Century Science for Innovative Medical Cures

As the U.S. Congress embarks on a first-of-its-kind initiative to help accelerate the pace of medical cures in America, Bentley professor Fred Ledley joined a panel of experts who testified at a congressional hearing in Washington, DC, on incentives for pharmaceutical and device development [...]

 


- 2013 -
(Back to top)


December 19, 2013

Bloomberg L.P. 
Fred Ledley on Bloomberg Radio: 2013 - A remarkable year for biotech (Audio)

Dr. Fred Ledley, Professor of Natural & Applied Sciences at Bentley University, speaks about the 60% increase of the biotechnology index and the impact on biotechnology IPOs.


December 3, 2013

Bentley University: PreparedU
Fred D. Ledley Named Fellow, American Association for the Advancement of Science

Fred D. Ledley, Professor of Natural & Applied Sciences and Management, and Director of the Center for Integration of Science and Industry, was named a fellow of the American Association for the Advancement of Science (AAAS). He will be recognized at the AAAS Annual Meeting in Chicago in February 2014 [...]


September 13, 2013

Bentley University: PreparedU
Post-doctoral Appointment Expand Focus of Center to Sustainable Energy Production

In order to expand its focus to areas of public health and sustainability, the Center for Integration of Science and Industry at Bentley University has appointed two post-doctoral fellows, Andrea Ballabeni, PhD and Michael J. Walsh, PhD [...]


March 5, 2013

Boston Business Journal
Researching Biotech Business Models

Bentley University is the recipient of a $1.3 million grant from the Boston-based National Biomedial Research Foundation, which is to be allocated to the newly created Center for Integration of Science and Industry (CISI) to fund research on biotech business models.


February 19, 2013

Bentley University: PreparedU
Bentley Receives $1.3M to Advance the Integration of Science and Business

The National Biomedical Research Foundation has awarded a $1.3M grant to Bentley University to establish a Center for Integration of Science and Industry, under the direction of Dr. Fred Ledley, Professor of Natural & Applied Sciences and Management [...]

 


- 2012 -
(back to top)


November 30, 2012

Management INK
Taking Business Education Into the Future

Professor Fred Ledley of Bentley University talks with editor Jane Schmidt-Wilk about his paper, co-authored by Stephen Holt of Olin College, which argues that business programs should require science courses designed expressly to meet the needs of business students.


October 10, 2012

Nature
Patterns of technological innovation in biotech

Theories of innovation posit that effective product development and value creation require business models and strategies matched to the stage of technology evolution. Such theories are predicated on patterns of technology evolution observed in other fields, where periods of exponential advancement are followed by limits and obsolescence as new technologies emerge [...]


August 1, 2012

The International Journal of Science in Society
Bridging the boundary between science and business

Concern about the adequacy of America’s scientific and technical workforce for an innovation-driven economy has led to a redoubling of efforts to graduate more students from postsecondary STEM programs. Less attention has focused on the role of STEM education for business professionals who are essential partners in generating economic value from scientific and technical advances [...]

 


July 1, 2012

Bentley University
Improving the Business of Science

The Center for Integration of Science and Industry (CISI) at Bentley University solicites a $1.3 million grant from the National Biomedical Research Foundation to fund its efforts in exploring how to translate great science into public value and help make a difference in the world.